More than 70 million Americans suffer from hair loss, 28.6% of whom are female. It is important for clinicians to take the initiative in discussing hair loss treatments with all patients, because despite the high prevalence, most patients incorrectly believe that no hair loss treatments are available, and therefore, do not request medical advice. However, hair loss treatments represent the second largest segment of aesthetic procedures in the United States.
The clinical approach to addressing the patient with hair loss is as follows :
Recent scientific research on hair growth pathways includes the following areas  :
Wnt signaling glycoprotein is a pathway in stem renewal, however, there are oncologic risks with chronic Wnt over activation. WAY-316606 is well-tolerated and specific antagonist of SFRP1 to prolong the growth phase of the hair cycle and has been shown to stimulate human hair growth in studies [2,3].
Other new research highlighted the following :
Eight new alopecia clinical trials are underway examining developments in JAK inhibitors, as they have shown promise for the treatment of alopecia areata, eczema (canines), vitiligo, and topical treatments for androgenic alopecia .
Nutraceutical supplements with standardized botanical extracts are emerging for the treatment of hair loss, including ashwanghanda, biocurcumin, and tocotrienosis. Deep-sea marine protein supplements are also available. Clinicians and researchers have found many botanicals effective for the treatment of androgenic alopecia.
Presenter disclosure(s): The presenter has reported relationships with the following company: Honoraria from Galderma Laboratories, L.P.
Written by: Daniel Bennett, MPH
Reviewed by: Martina Lambertini, MD